HIV EU

EUROPEAN COMMISSION GRANTS MARKETING …

Odefsey is the Second Single Tablet Regimen…

Foster City, Calif., 23 2016 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted marketing authorization for the once-daily single tablet regimen (STR) Odefsey (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the treatment of HIV-1 infection in certain patients.

Open »